Primary outcome
The primary outcome was a proportion of patients with the maximal hsTnI level more than 99th percentile value (> 15.6 ng/L) at the final cycle or 2-week post doxorubicin treatment. The primary outcome occurred in 24 (58.54%) patients in the metformin group, 30 (76.92%) in the donepezil group, and 30 (69.77%) in the placebo group (p-value = 0.215). These results are presented in Fig. Bar graph of primary outcome. Proportion of patients with hsTnI more than the 99th percentile cut-off value (> 15.6 ng/L) was presented. There was no significant different in the proportion of patients with hsTnI more than the cut-off value between placebo, metformin, and donepezil. 